Effect of Ex Vivo Culture of CD34+ Bone Marrow Cells on Immune Reconstitution of XSCID Dogs Following Allogeneic Bone Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 6, 2009, Pages 662-670

  Kennedy, Douglas R ^a   McLellan, Kyle ^a   Moore, Peter F ^b   Henthorn, Paula S ^a   Felsburg, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone marrow transplantation; Dog; Ex vivo culture; X linked SCID

Indexed keywords

CYTOKINE; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CD34 SELECTION; CELL STIMULATION; CONTROLLED STUDY; ENGRAFTMENT; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL CULTURE TECHNIQUES; CELL SEPARATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOGS; GENE THERAPY; GENETIC VECTORS; GRAFT SURVIVAL; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOGLOBULIN G; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LENTIVIRUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; RECOMBINANT FUSION PROTEINS; SEVERE COMBINED IMMUNODEFICIENCY; THYMUS GLAND; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 65549083294     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.03.014     Document Type: Article

References (57)

1. Krause D.S., Fackler M.J., Civin C.I., et al. CD34: structure, biology, and clinical utility. [see comments]. Blood 87 (1996) 1-13
2. Bensinger W.I., Clift R., Martin P., et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 88 (1996) 2794-2800
3. Morel F., Szilvassy S.J., Travis M., et al. Primitive hematopoietic cells in murine bone marrow express the CD34 antigen. Blood 88 (1996) 3774-3784
4. Berenson R.J., Andrews R.G., Bensinger W.I., et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 81 (1988) 951-955
5. Andrews R.G., Bryant E.M., Bartelmez S.H., et al. CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons. Blood 80 (1992) 1693-1701
6. McSweeney P.A., Rouleau K.A., Wallace P.M., et al. Characterization of monoclonal antibodies that recognize canine CD34. Blood 91 (1998) 1977-1986
7. Bruno B., Nash R.A., Wallace P.M., et al. CD34+ selected bone marrow grafts are radioprotective and establish mixed chimerism in dogs given high dose total body irradiation. Transplantation 68 (1999) 338-344
8. Hartnett B.J., Yao D.P., Suter S.E., et al. Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells. Biol. Blood Marrow Transpl 8 (2002) 188-197
9. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
10. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
11. Chinen J., Davis J., De Ravin S.S., et al. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 110 (2007) 67-73
12. Gaspar H.B., Bjorkegren E., Parsley K., et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 14 (2006) 505-513
13. Gaspar H.B., Parsley K.L., Howe S., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004) 2181-2187
14. Ginn S.L., Curtin J.A., Kramer B., et al. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Aust 182 (2005) 458-463
15. Ott M.G., Schmidt M., Schwarzwaelder K., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12 (2006) 401-409
16. Chang A.H., and Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Mol Ther 15 (2007) 445-456
17. Zielske S.P., and Gerson S.L. Cytokines, including stem cell factor alone, enhance lentiviral transduction in nondividing human LTCIC and NOD/SCID repopulating cells. Mol Ther 7 (2003) 325-333
18. Brugger W., Scheding S., Ziegler B., et al. Ex vivo manipulation of hematopoietic stem and progenitor cells. Semin Hematol 37 (2000) 42-49
19. Carlo-Stella C., Tabilio A., Regazzi E., et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant 20 (1997) 465-471
20. Galotto M., Berisso G., Delfino L., et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 27 (1999) 1460-1466
21. O'Flaherty E., Sparrow R., and Szer J. Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplant 15 (1995) 207-212
22. Plett P.A., Frankovitz S.M., Wolber F.M., et al. Treatment of circulating CD34(+) cells with SDF-1alpha or anti-CXCR4 antibody enhances migration and NOD/SCID repopulating potential. Exp Hematol 30 (2002) 1061-1069
23. Peters S.O., Kittler E.L., Ramshaw H.S., et al. Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol 23 (1995) 461-469
24. Varas F., Bernard A., and Bueren J.A. Restrictions in the stem cell function of murine bone marrow grafts after ex vivo expansion of short-term repopulating progenitors. Exp Hematol 26 (1998) 100-109
25. Brandt J.E., Bartholomew A.M., Fortman J.D., et al. Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons. Blood 94 (1999) 106-113
26. Abkowitz J.L., Taboada M.R., Sabo K.M., et al. The ex vivo expansion of feline marrow cells leads to increased numbers of BFU-E and CFU-GM but a loss of reconstituting ability. Stem Cells 16 (1998) 288-293
27. Goan S.R., Schwarz K., von Harsdorf S., et al. Fibroblasts retrovirally transfected with the human IL-3 gene initiate and sustain multilineage human hematopoiesis in SCID mice: comparison of CD34-enriched vs CD34-enriched and in vitro expanded grafts. Bone Marrow Transplant 18 (1996) 513-519
28. Guenechea G., Segovia J.C., Albella B., et al. Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood 93 (1999) 1097-1105
29. Rebel V.I., Tanaka M., Lee J.S., et al. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood 93 (1999) 2217-2224
30. Demaison C., Brouns G., Blundell M.P., et al. A defined window for efficient gene marking of severe combined immunodeficient-repopulating cells using a gibbon ape leukemia virus-pseudotyped retroviral vector. Hum Gene Ther 11 (2000) 91-100
31. Xu R., and Reems J.A. Umbilical cord blood progeny cells that retain a CD34+ phenotype after ex vivo expansion have less engraftment potential than unexpanded CD34+ cells. Transfusion 41 (2001) 213-218
32. Hows J.M. Status of umbilical cord blood transplantation in the year 2001. J Clin Pathol 54 (2001) 428-434
33. Glimm H., Schmidt M., Fischer M., et al. Evidence of similar effects of short-term culture on the initial repopulating activity of mobilized peripheral blood transplants assessed in NOD/SCID-beta2microglobulin(null) mice and in autografted patients. Exp Hematol 33 (2005) 20-25
34. Rosler E.S., Brandt J.E., Chute J., et al. An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells. Blood 96 (2000) 3414-3421
35. Felsburg P.J., Somberg R.L., Hartnett B.J., et al. Canine X-linked severe combined immunodeficiency. A model for investigating the requirement for the common gamma chain (gamma c) in human lymphocyte development and function. Immunol Res 17 (1998) 63-73
36. Felsburg P.J., Somberg R.L., Hartnett B.J., et al. Full immunologic reconstitution following nonconditioned bone marrow transplantation for canine X-linked severe combined immunodeficiency. Blood 90 (1997) 3214-3221
37. Henthorn P.S., Somberg R.L., Fimiani V.M., et al. IL-2R gamma gene microdeletion demonstrates that canine X-linked severe combined immunodeficiency is a homologue of the human disease. Genomics 23 (1994) 69-74
38. Wagner J.L., Burnett R.C., DeRose S.A., et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 62 (1996) 876-877
39. Sandmaier B.M., Fukuda T., Gooley T., et al. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. Exp Hematol 31 (2003) 168-175
40. Fukuda T., Kerbauy F.R., Gooley T., et al. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model. Transplantation 82 (2006) 332-339
41. Ting-De Ravin S.S., Kennedy D.R., Naumann N., et al. Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy. Blood 107 (2006) 3091-3097
42. Cobbold S., and Metcalfe S. Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens 43 (1994) 137-154
43. Moore P.F., Rossitto P.V., and Olivry T. Development of monoclonal antibodies to canine T cell receptor-γδ (TCR-γδ) and their utilization in the diagnosis of epidermotropic cutaneous T cell lymphoma. Vet. Pathol 31 (1994) 597
44. Kohn D.B. Gene therapy for genetic haematological disorders and immunodeficiencies. J Intern Med 249 (2001) 379-390
45. Devine S.M., Lazarus H.M., and Emerson S.G. Clinical application of hematopoietic progenitor cell expansion: current status and future prospects. Bone Marrow Transplant 31 (2003) 241-252
46. Greiner D.L., Hesselton R.A., and Shultz L.D. SCID mouse models of human stem cell engraftment. Stem Cells 16 (1998) 166-177
47. Kerre T.C., De Smet G., De Smedt M., et al. Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells. Blood 99 (2002) 1620-1626
48. Vernau W., Hartnett B.J., Kennedy D.R., et al. T cell repertoire development in XSCID dogs following nonconditioned allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 13 (2007) 1005-1015
49. Hacein-Bey-Abina S., Le Deist F., Carlier F., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346 (2002) 1185-1193
50. Fischer A., Le Deist F., Hacein-Bey-Abina S., et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 203 (2005) 98-109
51. Schmidt M., Hacein-Bey-Abina S., Wissler M., et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 105 (2005) 2699-2706
52. Schwarzwaelder K., Howe S.J., Schmidt M., et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117 (2007) 2241-2249
53. Ferrebee J.W., Lochte Jr. H.L., Jaretzki III A., et al. Successful marrow homograft in the dog after radiation. Surgery 43 (1958) 516-520
54. Thomas E.D., Lochte Jr. H.L., Cannon J.H., et al. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38 (1959) 1709-1716
55. Deeg H.J., Storb R., Weiden P.L., et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance. Transplantation 34 (1982) 30-35
56. Yu C., Seidel K., Nash R.A., et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91 (1998) 2581-2587
57. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054